ScripThe capital markets continue to shy away from relatively risky investments, such as drug development, providing new funding for a limited number of companies. That means a lot of biopharmaceutical fir
ScripWho: Merck KGaA/Caris Life Sciences What: Caris’s research division will discover novel targets for use in cancer antibody-drug conjugate products to be developed by Germany’s Merck. Why: Merck K
ScripJohnson & Johnson is beginning 2024 by making another bet on antibody-drug conjugates (ADCs) with the acquisition of Ambrx Biopharma, Inc. , which the drug maker announced shortly before CEO Joaquin
ScripUroGen Pharma, Ltd. anticipated filing for US Food and Drug Administration approval in 2024 for UGN-102 in the treatment of low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG-IR-NMI